Paper39441986
Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment.
Brettell SB and 16 others. J Med Chem, 2024. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment. Papers, record 39441986. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39441986
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Plasmodium falciparum | Major topic |
| Antimalarials | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Humans | |
| Protozoan Proteins | |
| Hep G2 Cells | |
| Structure-Activity Relationship | |
| Protein Serine-Threonine Kinases | |
| Malaria, Falciparum | |
| Crystallography, X-Ray | |
| Models, Molecular |
Source PubMed
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34355176 | Recent advances in the development of covalent inhibitors. | RSC Med Chem | 2021 | https://conductscience.org/library/papers/34355176 | PubMed |
| 2 | 28289248 | Antimalarial Drug Resistance: A Threat to Malaria Elimination. | Cold Spring Harb Perspect Med | 2017 | https://conductscience.org/library/papers/28289248 | PubMed |
| 3 | 28994500 | The Cysteinome of Protein Kinases as a Target in Drug Development. | Angew Chem Int Ed Engl | 2018 | https://conductscience.org/library/papers/28994500 | PubMed |
| 4 | 34921994 | Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. | Pharmacol Res | 2022 | https://conductscience.org/library/papers/34921994 | PubMed |
| 5 | 17521751 | Improved synchronous production of Plasmodium falciparum gametocytes in vitro. | Mol Biochem Parasitol | 2007 | https://conductscience.org/library/papers/17521751 | PubMed |
| 6 | 26272409 | Sexual development in Plasmodium parasites: knowing when it's time to commit. | Nat Rev Microbiol | 2015 | https://conductscience.org/library/papers/26272409 | PubMed |
| 7 | 37513939 | Covalent Inhibitors for Neglected Diseases: An Exploration of Novel Therapeutic Options. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37513939 | PubMed |
| 8 | 29131621 | Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity. | J Chem Inf Model | 2017 | https://conductscience.org/library/papers/29131621 | PubMed |
| 9 | 25075834 | Spread of artemisinin resistance in Plasmodium falciparum malaria. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25075834 | PubMed |
| 10 | 21460447 | Data processing and analysis with the autoPROC toolbox. | Acta Crystallogr D Biol Crystallogr | 2011 | https://conductscience.org/library/papers/21460447 | PubMed |
| 11 | 12929205 | The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. | PLoS Biol | 2003 | https://conductscience.org/library/papers/12929205 | PubMed |
| 12 | 11495584 | 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. | J Med Chem | 2001 | https://conductscience.org/library/papers/11495584 | PubMed |
| 13 | 37652975 | Antimalarial drug discovery: progress and approaches. | Nat Rev Drug Discov | 2023 | https://conductscience.org/library/papers/37652975 | PubMed |
| 14 | 33590753 | Plasmodium Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities. | ACS Infect Dis | 2021 | https://conductscience.org/library/papers/33590753 | PubMed |
| 15 | 31170268 | Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. | PLoS Pathog | 2019 | https://conductscience.org/library/papers/31170268 | PubMed |
| 16 | 31875044 | A Structurally-Validated Multiple Sequence Alignment of 497 Human Protein Kinase Domains. | Sci Rep | 2019 | https://conductscience.org/library/papers/31875044 | PubMed |
| 17 | 22127061 | Global kinomic and phospho-proteomic analyses of the human malaria parasite Plasmodium falciparum. | Nat Commun | 2011 | https://conductscience.org/library/papers/22127061 | PubMed |
| 18 | 30595467 | Plasmodium falciparum. | Trends Parasitol | 2019 | https://conductscience.org/library/papers/30595467 | PubMed |
| 19 | 29311509 | 7-Azaindole: A Versatile Scaffold for Developing Kinase Inhibitors. | Chem Pharm Bull (Tokyo) | 2018 | https://conductscience.org/library/papers/29311509 | PubMed |
| 20 | 31467193 | Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. | Science | 2019 | https://conductscience.org/library/papers/31467193 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42900459 | Emerging antimalarial drug targets to combat drug-resistant malaria parasites. | Infection | 2026 | https://conductscience.org/library/papers/42900459 | PubMed |
| 42680902 | New thinking for the next generation of antimalarials. | EMBO Mol Med | 2026 | https://conductscience.org/library/papers/42680902 | PubMed |
| 42363832 | Inhibition of PfCLK3 interferes with malaria parasite RNA splicing and explains the mechanism of action of a new class of antimalarial candidates. | Antimicrob Agents Chemother | 2026 | https://conductscience.org/library/papers/42363832 | PubMed |
| 42345078 | Using Unbiased Chemical Proteomics Approaches to Explore the Target Landscape of the Resistance Refractory 7-Azaindole MMV022224 in Plasmodium falciparum. | ACS Infect Dis | 2026 | https://conductscience.org/library/papers/42345078 | PubMed |
| 42127156 | Chemical genetics reveals Leishmania KKT2 and CRK9 kinase activity is required for cell cycle progression. | PLoS Pathog | 2026 | https://conductscience.org/library/papers/42127156 | PubMed |
| 41618901 | Shaping Antimalarials: A Geometry-First Approach to PfCLK3 Covalent Inhibitors. | J Med Chem | 2026 | https://conductscience.org/library/papers/41618901 | PubMed |
| 41131905 | Targeting Aurora Kinases as Essential Cell-Cycle Regulators to Deliver Multi-Stage Antimalarials Against Plasmodium Falciparum. | Angew Chem Int Ed Engl | 2025 | https://conductscience.org/library/papers/41131905 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39441986
GET https://conductscience.org/api/papers/v1/39441986/references?page=2